{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:29:05Z","timestamp":1789874945390,"version":"4.0.1"},"reference-count":56,"publisher":"The Journal of Health Economics and Outcomes Research","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHEOR"],"abstract":"<jats:p>Background: Few studies have estimated the real-world economic burden such as all-cause and follicular lymphoma-related costs and health care resource utilization (HCRU) in patients with follicular lymphoma (FL).  Objectives: This study evaluated outcomes in patients who were newly initiated with FL indicated regimens by line of therapy with real-world data.  Methods: A retrospective study was conducted among patients with FL from MarketScan\u00ae databases between January 1, 2010 and December 31, 2013. Patients were selected if they were \u226518 years old when initiated on a FL indicated therapy, had at least 1 FL-related diagnosis, \u22651 FL commonly prescribed systemic anti-cancer therapy after diagnosis, and did not use any FL indicated regimen in the 24 months prior to the first agent. These patients were followed up at least 48 months and the outcomes, including the distribution of regimens by line of therapy, the treatment duration by line of therapy, all-cause and FL-related costs, and HCRU by line of therapy were evaluated.  Results: This study identified 598 patients who initiated FL indicated treatment. The average follow-up time was approximately 5.7 years. Of these patients, 50.2% (n=300) were female, with a mean age of 60.7 years (SD=13.1 years) when initiating their treatment with FL indicated regimens. Overall, 598 (100%) patients received first-line therapy, 180 (43.6%) received second-line therapy, 51 received third-line therapy, 21 received fourth-line therapy, and 10 received fifth-line therapy. Duration of treatment by each line of therapy was 370 days, 392 days, 162 days, 148 days, and 88 days, respectively. The most common first-line regimens received by patients were rituximab (n=201, 33.6%), R-CHOP (combination of rituximab, cyclophosphamide, doxorubicin hydrochloride [hydroxydaunomycin]; n=143, 24.0%), BR (combination of bendamustine and rituximab; n=143, 24.0%), and R-CVP (combination of rituximab, cyclophosphamide, vincristine, and prednisone; n=71, 11.9%). The most common second-line treatment regimens were (N=180): rituximab (n=78, 43.3%) and BR (n=41, 22.8%). Annualized all-cause health care costs per patient ranged from US$97\u202f141 (SD: US$144\u202f730) for first-line to US$424\u202f758 (SD: US$715\u2009028) for fifth-line therapy.  Conclusions: The primary regimens used across treatment lines conform to those recommended by the National Comprehensive Cancer Network clinical practice guidelines. The economic burden for patients with FL is high and grows with subsequent lines of therapy.<\/jats:p>","DOI":"10.36469\/jheor.2020.16784","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T18:16:26Z","timestamp":1599243386000},"page":"148-157","source":"Crossref","is-referenced-by-count":10,"title":["reatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma"],"prefix":"10.36469","author":[{"given":"Nathan","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2023]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276. doi:10.1182\/blood-2005-06-2508","DOI":"10.1182\/blood-2005-06-2508"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood. 2002;99(12):4265-4275. doi:10.1182\/blood.v99.12.4265","DOI":"10.1182\/blood.V99.12.4265"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayoclinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31(26):3272-3278. doi:10.1200\/jco.2012.48.3990","DOI":"10.1200\/JCO.2012.48.3990"},{"key":"ref3","unstructured":"Ghielmini M, Vitolo U, Kimby E, et al. Esmo guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large b-cell lymphoma (Dlbcl) follicular lymphoma"},{"key":"ref4","unstructured":"(Fl) and chronic lymphocytic leukemia (Cll. Annals of Oncology. 2012;24(3):561-576."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443-459. doi:10.3322\/caac.21357","DOI":"10.3322\/caac.21357"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Monga N, Nastoupil L, Garside J, et al. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019;98(1):175-183. doi:10.1007\/s00277-018-3501-8","DOI":"10.1007\/s00277-018-3501-8"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Binkley MS, Brady JL, Hajj C, et al. Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: A collaborative study on behalf of ilrog. Int J Radiat Oncol Biol Phys. 2019;104(3):522-529. doi:10.1016\/j.ijrobp.2019.03.004","DOI":"10.1016\/j.ijrobp.2019.03.004"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Brady JL, Binkley MS, Hajj C, et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: A collaborative study by ILROG. Blood. 2019;133(3):237-245. doi:10.1182\/blood-2018-04-843540","DOI":"10.1182\/blood-2018-04-843540"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Shirley MH, Sayeed S, Barnes I, Finlayson A, Ali R. Incidence of haematological malignancies by ethnic group in England, 2001-7. Br J Haematol. 2013;163(4):465-477. doi:10.1111\/bjh.12562","DOI":"10.1111\/bjh.12562"},{"key":"ref10","unstructured":"Howlader NA, Krapcho M, Miller D, et al., eds. Seer Cancer Statistics Review 1975-2016. National Cancer Institute"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii83-iii92. doi:10.1093\/annonc\/mdu264","DOI":"10.1093\/annonc\/mdu264"},{"key":"ref12","unstructured":"The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae. B-Cell Lymphmoas. Version 5.2018.; 2018. http:\/\/www.nccn.org"},{"key":"ref13","unstructured":"Kahl BS. Current treatment approaches in follicular lymphoma. Clin Adv Hematol Oncol. 2015;13(11):740-743."},{"key":"ref14","unstructured":"About Lumphoma. Follicular Lymphoma: Relapsed\/Refractory. Lymphoma Research Foundation. Published 2020. Accessed July 21, 2020. https:\/\/lymphoma.org\/Aboutlymphoma\/Nhl\/Fl\/Relapsedfl\/"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 2002;99(10):3806-3812. doi:10.1182\/blood.v99.10.3806","DOI":"10.1182\/blood.V99.10.3806"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Flinn IW, Miller CB, Ardeshna KM, et al. Dynamo: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 2019;37(11):912-922. doi:10.1200\/jco.18.00915","DOI":"10.1200\/JCO.18.00915"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Salles G, Schuster SJ, de Vos S, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study. Haematologica. 2017;102(4):e156-e159. doi:10.3324\/haematol.2016.151738","DOI":"10.3324\/haematol.2016.151738"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Ekstr\u00f6m-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma - a review. Acta Oncol. 2006;45(3):258-271. doi:10.1080\/02841860500531682","DOI":"10.1080\/02841860500531682"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Fowler N. Frontline strategy for follicular lymphoma: Are we ready to abandon chemotherapy? Hematology Am Soc Hematol Educ Program. 2016;2016(1):277-283. doi:10.1182\/asheducation-2016.1.277","DOI":"10.1182\/asheducation-2016.1.277"},{"key":"ref20","unstructured":"Meyer N, Song X, Gregory SA, Ramsey DS. Treatment patterns mortality and health care utilization and costs in indolent non-hodgkin lymphoma patients with relapsed or refractory disease. Asco Abstract. Published online 2017."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Morrison VA, Shou Y, Bell JA, et al. Treatment patterns and survival outcomes in patients with follicular lymphoma: A 2007 to 2015 humedica database study. Clin Lymphoma Myeloma Leuk. 2019;19(4):e172-e183. doi:10.1016\/j.clml.2018.12.017","DOI":"10.1016\/j.clml.2018.12.017"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Appukkuttan S, Duchesneau E, Zichlin ML, et al. A budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States. J Manag Care Spec Pharm. 2019:1-12.","DOI":"10.18553\/jmcp.2019.18259"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Wang HI, Smith A, Aas E, et al. Treatment cost and life expectancy of diffuse large b-cell lymphoma (DLBCL): A discrete event simulation model on a UK population-based observational cohort. Eur J Health Econ. 2017;18(2):255-267. doi:10.1007\/s10198-016-0775-4","DOI":"10.1007\/s10198-016-0775-4"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Mounier M, Bossard N, Belot A, et al. Trends in excess mortality in follicular lymphoma at a population level. Eur J Haematol. 2015;94(2):120-129. doi:10.1111\/ejh.12403","DOI":"10.1111\/ejh.12403"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Pettengell R, Donatti C, Hoskin P, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol. 2008;19(3):570-576. doi:10.1093\/annonc\/mdm543","DOI":"10.1093\/annonc\/mdm543"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Carter GC, Liepa AM, Zimmermann AH, Morschhauser F. Validation of the functional assessment of cancer therapy-lymphoma (fact-lym) in patients with relapsed\/refractory mantle cell lymphoma. Blood. 2008;112(11):2376-2376. doi:10.1182\/blood.v112.11.2376.2376","DOI":"10.1182\/blood.V112.11.2376.2376"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large b-cell and follicular lymphoma treated in the USA. Future Oncol. 2018;14(25):2627-2642. doi:10.2217\/fon-2018-0267","DOI":"10.2217\/fon-2018-0267"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Wang HI, Roman E, Crouch S, et al. A generic model for follicular lymphoma: predicting cost life expectancy and quality-adjusted-life-year using UK population-based observational data. Value Health. 2018;21(10):1176-1185. doi:10.1016\/j.jval.2018.03.007","DOI":"10.1016\/j.jval.2018.03.007"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma. 2008;8(3):166-170. doi:10.3816\/clm.2008.n.020","DOI":"10.3816\/CLM.2008.n.020"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Hornberger J, Chien R, Friedmann M, et al. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. Leuk Lymphoma. 2012;53(12):2371-2377. doi:10.3109\/10428194.2012.694429","DOI":"10.3109\/10428194.2012.694429"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol. 2008;47(6):1029-1036. doi:10.1080\/02841860802120028","DOI":"10.1080\/02841860802120028"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Ray JA, Carr E, Lewis G, Marcus R. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-hodgkin's lymphoma in the UK. Value Health. 2010;13(4):346-357. doi:10.1111\/j.1524-4733.2009.00676.x","DOI":"10.1111\/j.1524-4733.2009.00676.x"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Deconinck E, Miadi-Fargier H, Pen CL, Brice P. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: Long-term economic evaluation. Pharmacoeconomics. 2010;28(1):35-46. doi:10.2165\/11314070-000000000-00000","DOI":"10.2165\/11314070-000000000-00000"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Soini EJO, Martikainen JA, Nousiainen T. Treatment of follicular non-hodgkin's lymphoma with or without rituximab: Cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189-1197. doi:10.1093\/annonc\/mdq582","DOI":"10.1093\/annonc\/mdq582"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Griffiths RI, Gleeson ML, Mikhael J, Danese MD. Impact on medical cost cumulative survival and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on seer-medicare. J Cancer Epidemiol. 2012;2012:1-13. doi:10.1155\/2012\/978391","DOI":"10.1155\/2012\/978391"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Blommestein HM, Issa DE, Pompen M, et al. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: Results of a population-based study. Eur J Haematol. 2014;92(5):398-406. doi:10.1111\/ejh.12264","DOI":"10.1111\/ejh.12264"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Prica A, Chan K, Cheung M. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis. Cancer. 2015;121(15):2637-2645. doi:10.1002\/cncr.29372","DOI":"10.1002\/cncr.29372"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Dewilde S, Woods B, Castaigne JG, Parker C, Dunlop W. Bendamustine-rituximab: A cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. J Med Econ. 2014;17(2):111-124. doi:10.3111\/13696998.2013.873044","DOI":"10.3111\/13696998.2013.873044"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Pink J, Lane S, Hughes DA. Mechanism-based approach to the economic evaluation of pharmaceuticals: Pharmacokinetic\/pharmacodynamic\/pharmacoeconomic analysis of rituximab for follicular lymphoma. Pharmacoeconomics. 2012;30(5):413-429. doi:10.2165\/11591540-000000000-00000","DOI":"10.2165\/11591540-000000000-00000"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Dundar Y, Bagust A, Hounsome J, et al. Rituximab for the first-line treatment of stage III\/IV follicular non-hodgkin's lymphoma. Health Technol Assess. 2009;13(Suppl 1):23-28. doi:10.3310\/hta13suppl1\/04","DOI":"10.3310\/hta13Suppl1\/04"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Boland A, Bagust A, Hockenhull J, Davis H, Chu P, Dickson R. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin's lymphoma. Health Technol Assess. 2009;13(Suppl 2):41-48. doi:10.3310\/hta13suppl2\/06","DOI":"10.3310\/hta13suppl2\/06"},{"key":"ref42","unstructured":"Marketscan Research Databases. Accessed December 12, 2019. https:\/\/www.ibm.com\/Us-En\/Marketplace\/Marketscan-Research-Databases"},{"key":"ref43","unstructured":"IBM Marketscan Research Databases for Life Sciences Researchers. Accessed December 12, 2019. https:\/\/www.ibm.com\/downloads\/Cas\/Owzwj0qo"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2-10. doi:10.1002\/pds.3891","DOI":"10.1002\/pds.3891"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (strobe): Explanation and elaboration. Ann Intern Med. 2007;147(8):W. doi:10.7326\/0003-4819-147-8-200710160-00010-w1","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"World Medical Association. World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001\/jama.2013.281053","DOI":"10.1001\/jama.2013.281053"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780-2795. doi:10.1200\/jco.1998.16.8.2780","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-383. doi:10.1016\/0021-9681(87)90171-8","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"ref49","unstructured":"The National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Follicular Lymphoma Grade 1-2. Published online 2019. Accessed December 20, 2019. https:\/\/www.nccn.org\/patients\/guidelines\/nhl-follicular\/10\/"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies. Cancer Manag Res. 2013;5:251-269. doi:10.2147\/cmar.s34273","DOI":"10.2147\/CMAR.S34273"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Link BK, Day BM, Zhou X, et al. Second\u2010line and subsequent therapy and outcomes for follicular lymphoma in the United States: Data from the observational National LymphoCare Study. Br J Haematol. 2019;184(4):660-663. doi:10.1111\/bjh.15149","DOI":"10.1111\/bjh.15149"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Bruna R, Benedetti F, Boccomini C, et al. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. Haematologica. 2019;104(11):2241-2248. doi:10.3324\/haematol.2018.209932","DOI":"10.3324\/haematol.2018.209932"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019;133(14):1540-1547. doi:10.1182\/blood-2018-08-822148","DOI":"10.1182\/blood-2018-08-822148"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide doxorubicin vincristine and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-2522. doi:10.1200\/jco.2014.59.7534","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Maziarz RT, Hao Y, Guerin A, et al. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large b-cell lymphoma. Leuk Lymphoma. 2018;59(5):1133-1142. doi:10.1080\/10428194.2017.1375100","DOI":"10.1080\/10428194.2017.1375100"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"link":[{"URL":"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/pmid\/33043061\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:40:39Z","timestamp":1748875239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/16784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":56,"URL":"https:\/\/doi.org\/10.36469\/jheor.2020.16784","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}